PTC Therapeutics, Inc. (PTCT): Price and Financial Metrics
PTCT Stock Summary
- Of note is the ratio of Ptc Therapeutics Inc's sales and general administrative expense to its total operating expenses; just 17.75% of US stocks have a lower such ratio.
- PTCT's price/sales ratio is 10.51; that's higher than the P/S ratio of 83.33% of US stocks.
- In terms of twelve month growth in earnings before interest and taxes, Ptc Therapeutics Inc is reporting a growth rate of 74.92%; that's higher than 85.04% of US stocks.
- Stocks that are quantitatively similar to PTCT, based on their financial statements, market capitalization, and price volatility, are KDMN, XFOR, OMER, SIMO, and SILC.
- Visit PTCT's SEC page to see the company's official filings. To visit the company's web site, go to www.ptcbio.com.
PTCT Stock Price Chart Interactive Chart >
PTCT Price/Volume Stats
| Current price | $57.10 | 52-week high | $70.82 |
| Prev. close | $55.19 | 52-week low | $30.79 |
| Day low | $54.00 | Volume | 972,400 |
| Day high | $57.68 | Avg. volume | 543,211 |
| 50-day MA | $62.68 | Dividend yield | N/A |
| 200-day MA | $54.94 | Market Cap | 3.90B |
PTC Therapeutics, Inc. (PTCT) Company Bio
PTC Therapeutics is a global biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small molecule drugs targeting an area of RNA biology we refer to as post-transcriptional control. The company was founded in 1998 and is based in South Plainfield, New Jersey.
Latest PTCT News From Around the Web
Below are the latest news stories about Ptc Therapeutics Inc that investors may wish to consider to help them evaluate PTCT as an investment opportunity.
PTC Therapeutics, Inc (PTCT) CEO Stuart Peltz on Q4 2020 Results - Earnings Call TranscriptPTC Therapeutics, Inc (PTCT) Q4 2020 Earnings Conference Call February 25, 2021 16:30 PM ET Company Participants Kylie O'Keefe - Head of Investor Relations Stuart Peltz - Founder and Chief Executive Officer Emily Hill - Chief Financial Officer Eric Pauwels - Chief Business Officer Matthew Klein - Chief Development Officer... |
CHMP Adopts Positive Opinion for Evrysdi™ for the Treatment of Spinal Muscular Atrophy in Adults and Children Aged Two Months and OlderPTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Evrysdi™ (risdiplam) for the treatment of 5q spinal muscular atrophy (SMA) in patients 2 months and older, with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 with one to four SMN2 copies. The CHMP review was completed under the accelerated assessment pathway, which is offered to medicines deemed to be of major interest for public health and therapeutic innovation. |
PTC Therapeutics (PTCT) Reports Q4 Loss, Tops Revenue EstimatesPTC Therapeutics (PTCT) delivered earnings and revenue surprises of -20.00% and 4.76%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock? |
Positive Data from FIREFISH Study of Evrysdi™ (risdiplam) in Infants with Type 1 Spinal Muscular Atrophy Published in The New England Journal of MedicinePTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the publication of results from the dose finding Part 1 of the pivotal FIREFISH study evaluating Evrysdi™ (risdiplam) in infants with symptomatic type 1 spinal muscular atrophy (SMA) in The New England Journal of Medicine (NEJM). The Part 1 data showed that patients treated with Evrysdi at 12 months demonstrated significant improvement in survival and developmental milestones, including the ability to survive without permanent ventilation, and the ability to sit without support for at least five seconds. Data from the study also demonstrated increased levels of survival motor neuron (SMN) protein, which is critical for maintaining nerve and muscle function. |
PTC Therapeutics Reports the Initiation of the Second Stage of the FITE19 Phase 2/3 Clinical Trial Evaluating PTC299 for the Treatment of COVID-19PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the initiation of the second stage of the FITE19 clinical trial to assess PTC299 in COVID-19 patients. PTC299 is an oral investigational drug with a novel dual mechanism of action that has the potential to inhibit viral replication and attenuate the uncontrolled inflammatory response that ensues after infection. PTC299 functions by targeting a cellular enzyme, dihydroorotate dehydrogenase (DHODH). By targeting this enzyme instead of a viral protein, it makes it less likely to elicit drug-resistance. Enrollment for the second stage of the trial has been initiated in multiple centers outside of the US. |
PTCT Price Returns
| 1-mo | -1.25% |
| 3-mo | -9.06% |
| 6-mo | 13.43% |
| 1-year | 4.12% |
| 3-year | 121.92% |
| 5-year | 792.19% |
| YTD | -6.44% |
| 2020 | 27.07% |
| 2019 | 39.95% |
| 2018 | 105.76% |
| 2017 | 52.89% |
| 2016 | -66.33% |
Continue Researching PTCT
Want to do more research on Ptc Therapeutics Inc's stock and its price? Try the links below:Ptc Therapeutics Inc (PTCT) Stock Price | Nasdaq
Ptc Therapeutics Inc (PTCT) Stock Quote, History and News - Yahoo Finance
Ptc Therapeutics Inc (PTCT) Stock Price and Basic Information | MarketWatch
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...